Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ross Stores, Inc. (ROST) vs TransMedics Group Inc (TMDX) Price & Performance

Ross Stores, Inc.Trade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Ross Stores, Inc. vs TransMedics Group Inc — how do they compare? Ross Stores, Inc. trades at $247.52 (market cap $80.78B), while TransMedics Group Inc trades at $87.29 (market cap $3.10B). The key difference: Ross Stores, Inc. is far larger — about 26.1× TransMedics Group Inc's market cap, and Ross Stores, Inc. pays a 0.71% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

ROSTTMDX
Market Cap
$80.78B$3.10B
Sector
Consumer CyclicalTechnology
52-Week High
$255.23$150.42
52-Week Low
$144.67$61.99
Enterprise Value
$81.37B$3.49B
Dividend Yield
0.71%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ross Stores, Inc.

ROST trades at $250.45, down 1.72% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $259.00. The company has consistently beaten earnings estimates, with Q1 2026 EPS of $2.02 exceeding the $1.73 forecast. Strong fundamentals include a net income margin of 9.74% and ROE of 38.98%, supported by revenue growth to $21.13 billion in 2025 and recent expansion with 47 new stores opened in mid-2026.

The outlook remains positive given earnings momentum and store growth, but elevated valuation ratios like a P/E of 35.17 pose a risk if growth slows. Analyst sentiment is bullish with 64% buy ratings, though technical indicators show mixed signals with RSI near overbought levels. Investors should weigh robust profitability against high multiples in a competitive retail sector.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.

The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.

Returns comparison

Trailing returns across standard periods

About Ross Stores, Inc.

Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach

Read more on ROST

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX